Company
Destiny Pharma PLC
LON:DEST
Destiny Pharma PLC is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.
97 stories · page 5 of 5
Investments and investor services
FTSE 100 closes near flat as traders sit on hands ahead of Fed
The UK blue-chip index closed nearly four points higher at 7,511
Archive
Expected US interest rate hike to draw the attention Wednesday, as Trump trade wars rumble on
Aside from the US interest rate decision, corporate updates are due from online fashion retailer Boohoo Group, outsourcer MITIE, and automotive services firm The AA ...
Archive
US interest rate hike eyed, as retailers, tour operators and utilities provide updates in coming week
Aside from the latest Federal Reserve policy meeting, the week ahead will bring updates from the likes of Next, Thomas Cook, TUI, United Utilities, and Pennon
Investments and investor services
FTSE 100 closes near flat as Middle East tensions cool
The UK blue-chip benchmark closed 1.20 points, or 0.02% at 7,258..
Archive
Travel sales set to dominate at WH Smith once again on Thursday; Hays and Saga also due up
It looks like it will be the same old story for WH Smith, with sales flying in travel but challenges remaining in its high street stores
Archive
Retailers and recruiters in focus as Tesco, ASOS, Hays and PageGroup report
The week ahead includes full-year results from Tesco and Saga, interims from ASOS, WH Smith and McCarthy & Stone, and trading updates from Robert Walters, Hays and PageGroup
Antibiotic developer Destiny Pharma rockets as Chinese partner invests £3mln at hefty premium
The money will be used for a Phase IIb clinical trial of its lead programme XF-73
TI Fluid Systems revives IPO plans in latest show of confidence in markets
Several companies have either joined the London market or announced they are going to over the past six weeks or so
Destiny Pharma believes it has the answer to superbug threat
The urgency and size of the market offers huge potential for any company that can come up with a new way to treat infections safely
FTSE 100 steadily extends gains
There has been no news flow from FTSE 100 companies to speak of today
Archive
Hotel Chocolat feeling the heat; Boohoo.com tipped to produce the goods once again
It's not been a sweet run for Hotel Chocolat shares recently, investors will be looking to see if the chocolatier's outlook can change that on Wednesday...
Archive
Focus on tour operators TUI and Thomas Cook and utilities in week ahead
Week ahead includes trading updates from tour operators TUI AG and Thomas Cook Group PLC, and numbers from Pennon Group PLC and United Utilities PLC
New float Destiny Pharma's shares race to a 30% debut premium
The company, only the second biotech float this year, is bringing through a next-generation antibiotic